Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q3 2019 · 10-Q
Revenue$9.15M$9.15M−13.5% vs Q3 2018 Net Income$41.30K$41.30K−99.3% vs Q3 2018 EPS Diluted-$0.03-$0.03N/M vs Q3 2018 Gross Profit$1,899,451−19.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
Operating Cash Flowderived-$500,130N/M Margins · derivedGross margin20.8%−1.4 pt vs Q3 2018
Operating margin-17.1%−74.8 pt vs Q3 2018
Net margin0.5%−53.4 pt vs Q3 2018
ended Sep 30, 2019 · filed Nov 8, 2019 · 39 d after period end